https://www.selleckchem.com/pr....oducts/ly3537982.htm
Although only a small number of venom peptides have successfully progressed to the clinic, there is reason to be optimistic about their development as anti-epileptic drugs, notwithstanding the challenges associated with development of any class of peptide drug.Small molecules targeting the PD-1/PD-L1 immune checkpoint are actively searched to offer anticancer oral treatment modalities. Different small molecules have been designed, such as BMS-202 and BMS-1166 which potently bind to PD-L1, sequestering the protein dimer and thus preven
Like
Comment
Share
